Inclusion Criteria:  Age between 18 and 75; Untreated patients with pathologically proven locally advanced cervical cancer; Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1  Adequate hematological, renal and hepatic functions:  Hemoglobin > 8.0 g/dl Neutrophils > 2000 cells/μl; Leukocytes > 4 × 109/L Platelets > 100 × 109/L  g. Serum urea nitrogen (BUN) ≤ 1.5 × upper normal limit (UNL) h. Serum creatinine (Cr) ≤ 1.5 × upper normal limit (UNL) d. Serum ALT/AST ≤ 2.5× UNL e. Serum Total bilirubin ≤ 1.5× UNL  Life expectancy > 6 months Eligible for concurrent chemoradiotherapy assessed by principle investigator; No obvious active bleeding; Written informed consent must be available before study registration  Exclusion Criteria:  Recurrent or distant metastatic disease; Prior malignancies (other than curable non-melanoma skin cancer) within 5 years; Active autoimmune diseases requiring systemic treatment or other diseases requiring long-term use of substantial amount of hormones or other immunosuppressants; Patients who need to receive systemic corticosteroids (dose equivalent to or higher than prednisone 10mg qd) or other immunosuppressants within 14 days before enrollment or during the study; Vaccination of live attenuated vaccine 30 days before enrollment, or planned vaccination of live attenuated vaccine during the study; Previous organ transplantation or HIV patients; Allergic to macromolecular proteins /monoclonal antibodies, or to any test drug component; Active acute or chronic viral hepatitis B or C. Hepatitis B virus (HBV) DNA> 2000IU/ml or 104 copies/ml; hepatitis C virus (HCV) RNA> 103 copies/ml.